Nijmegen, the Netherlands-based Enzyre, a Radboud University Medical Center spin-out, announced on Wednesday, November 2, that it has secured $12M (approximately €12.2M) in a Series A round of funding.
The round was led by new investor Oost NL, with participation from i&i Biotech Fund, Demcon Investment, and existing investors Takeda Ventures and Novalis Biotech.
A part of the funding is an Innovation Credit from the Dutch Government.
The proceeds from the round will further enable the Dutch company to develop its diagnostic technology platform, EnzyPad.
Enzyre says it will also use the capital to support clinical trial registrations, establish a sustainable manufacturing line, and invest in expanding applications in the critical care setting.
Guido Maertens, Chief Executive Officer of Enzyre, says, “We are delighted to have closed this successful financing round which validates our technology and will underpin our ongoing development as we take Enzyre forward into the next phase of growth. We value Takeda’s continued support and welcome the commitment from a strong cohort of new and existing investors. Together we look forward to improving the quality of life for patients with bleeding disorders by driving forward our goal to transform their standard of care.”
Enzyre: What you need to know
Founded by Waander van Heerde and Guido Maertens, Enzyre aims to develop a diagnostic device to give patients the flexibility to assess their coagulation status regardless of where they are.
Dubbed Hemophilia EnzyCard, the company uses its proprietary EnzyPad platform technology to determine the coagulation status of patients with haemophilia. This rare genetic disorder is estimated to affect over 800,000 people worldwide.
“Those with haemophilia A lack sufficient blood-clotting factor VIII (FVIII) activity, causing them to bleed for longer after an injury than healthy subjects,” says the company.
Enzyre’s technology will allow patients to conduct self-tests in the comfort of their own homes and eventually share their coagulation status with their treating physician through a mobile phone app and cloud-based application.
As a result, timely, personalised therapy adjustments may improve clinical outcomes while avoiding unnecessary travel, hospital exposure, and overall treatment burden and cost for patients and healthcare systems.
Oost NL is the development company of the Eastern Netherlands. It is strengthening the regional economy on behalf of the Ministry of Economic Affairs and Climate Policy and the provinces of Overijssel and Gelderland, by investing public money in entrepreneurs in the east of the Netherlands.
In addition to these financial resources, Oost NL also makes its knowledge, expertise and network available. It is active in the top sectors – Food, Energy, Health, Tech and Circular Economy.
Pieter Rhemrev, senior investment manager at Oost NL, acting as lead investor of the syndicate, says, “We are excited to be working with Enzyre in developing a truly innovative technology that is a potential game changer in the management of Haemophilia A and other bleeding disorders. Patient outcomes and quality of life will be dramatically improved by the ability of physicians to monitor coagulation status in real time. In addition, we see great potential for the product to enhance personalised care. We look forward to joining this talented team and our syndicate partners in supporting Enzyre’s pathway to future success.”